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INTRODUCTION
Cancer known medically as a malignant neoplasm, is a large group of
different diseases, all involving unregulated cell growth. In cancer, cells divide and
grow uncontrollably, forming malignant tumors, and invade nearby parts of the
body. The cancer may also spread to more distant parts of the body through
the lymphatic system or bloodstream. Not all tumors are cancerous. Benign
tumors do not grow uncontrollably, do not invade neighboring tissues, and do not
spread throughout the body.
Determining what causes cancer is complex. Many things are known to
increase the risk of cancer, including tobacco use, certain infections, radiation, lack
of physical activity, poor diet and obesity, and environmental pollutants. These can
directly damage genes or combine with existing genetic faults within cells to cause
the disease. Approximately five to ten percent of cancers are entirely hereditary.
Cancer can be detected in a number of ways, including the presence of
certain signs and symptoms, screening tests, or medical imaging. Once a possible
cancer is detected it is diagnosed by microscopic examination of a tissue sample.
Cancer is usually treated with chemotherapy, radiation therapy and surgery. The
chances of surviving the disease vary greatly by the type and location of the cancer
and the extent of disease at the start of treatment. While cancer can affect people of
all ages, and a few types of cancer are more common in children, the risk of
developing cancer generally increases with age. In 2007, cancer caused about 13%
of all human deaths worldwide (7.9 million). Rates are rising as more people live to
an old age and as mass lifestyle changes occur in the developing world.
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HISTORY
The earliest written record regarding cancer is from 3000 BC in the
Egyptian Edwin Smith Papyrus and describes cancer of the breast. Cancer however
has existed for all of human history. Hippocrates (ca. 460 BC – ca. 370 BC)
described several kinds of cancer, referring to them with
the Greek word carcinos (crab or crayfish). This name comes from the appearance
of the cut surface of a solid malignant tumour, with "the veins stretched on all sides
as the animal the crab has its feet, whence it derives its name". The
Greek, Celsus (ca. 25 BC - 50 AD) translated carcinos into the Latin cancer, also
meaning crab and recommended surgery as treatment. Galen (2nd century AD)
disagreed with the use of surgery and recommended purgatives instead. These
recommendations largely stood for 1000 years.
In the 15th, 16th and 17th centuries, it became more acceptable for doctors
to dissect bodies to discover the cause of death. The German professor Wilhelm
Fabry believed that breast cancer was caused by a milk clot in a mammary duct. The
Dutch professor Francois de la Boe Sylvius, a follower of Descartes, believed that
all disease was the outcome of chemical processes, and that acidic lymph fluid was
the cause of cancer. His contemporary Nicolaes Tulp believed that cancer was a
poison that slowly spreads, and concluded that it was contagious.
The physician John Hill described tobacco snuff as the cause of nose cancer
in 1761. This was followed by the report in 1775 by British surgeon Percivall
Pott that cancer of the scrotum was a common disease among chimney sweeps. With
the widespread use of the microscope in the 18th century, it was discovered that the
'cancer poison' spread from the primary tumor through the lymph nodes to other
sites ("metastasis"). This view of the disease was first formulated by the English
surgeon Campbell De Morgan between 1871 and 1874.
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SIGNS AND SYMPTOMS
When cancer begins it invariably produces no symptoms with signs and
symptoms only appearing as the mass continue to grow ulcerates. The findings that
result depend on the type and location of the cancer. Few symptoms are specific,
with many of them also frequently occurring in individuals who have other
conditions. Cancer is the new "great imitator". Thus it is not uncommon for people
diagnosed with cancer to have been treated for other diseases to which it was
assumed their symptoms were due.
LOCAL EFFECTS
Local symptoms may occur due to the mass of the tumor or its ulceration.
For example mass effects from lung cancer can cause blockage of
the bronchus resulting in cough or pneumonia, esophageal cancer can cause
narrowing of the esophagus making it difficult or painful to swallow, and colorectal
cancer may lead to narrowing or blockages in the bowel resulting in changes in
bowel habits. Masses of breast or testicles may be easily felt. Ulceration can cause
bleeding which, if it occurs in the lung, will lead to coughing up blood, in the
bowels to anemia or rectal bleeding, in the bladder to blood in the urine, and in the
uterus to vaginal bleeding. Although localized pain may occurs in advanced cancer,
the initial swelling is usually painless. Some cancers can cause build up of fluid
within the chest or abdomen.
SYSTEMIC SYMPTOMS
General symptoms occur due to distant effects of the cancer that are not
related to direct or metastatic spread. These may include: unintentional weight
loss, fever, being excessively tired, and changes to the skin. Hodgkin disease,
leukemias, and cancers of the liver or kidney can cause a persistent fever of
unknown origin.
Specific constellations of systemic symptoms, termed paraneoplastic
phenomenone, may occur with some cancers. Examples include the appearance
of myasthenia gravis in thymoma and clubbing in lung cancer.
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METASTASIS
Symptoms of metastasis are due to the spread of cancer to other locations in
the body. They can include enlarged lymph nodes (which can be felt or sometimes
seen under the skin and are typically hard), hepatomegaly (enlarged liver)
or splenomegaly (enlarged spleen) which can be felt in the abdomen, pain
or fracture of affected bones, and neurological symptoms. (Moscow et al., 2007)
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CAUSES
Cancers are primarily an environmental disease with 90-95% of cases
attributed to environmental factors and 5-10% due to genetics. Environmental, as
used by cancer researchers, means any cause that is not genetic, not merely
pollution. Common environmental factors that contribute to cancer death
include tobacco (25-30%), diet and obesity (30-35%), infections (15-
20%), radiation (both ionizing and non-ionizing, up to 10%), stress, lack of physical
activity, and environmental pollutants.
It is nearly impossible to prove what caused a cancer in any individual,
because most cancers have multiple possible causes. For example, if a person who
uses tobacco heavily develops lung cancer, then it was probably caused by the
tobacco use, but since everyone has a small chance of developing lung cancer as a
result of air pollution or radiation, then there is a small chance that the cancer
developed because of air pollution or radiation.
CHEMICALS
Cancer pathogenesis is traceable back to DNA mutations that impact cell
growth and metastasis. Substances that cause DNA mutations are known as
mutagens, and mutagens that cause cancers are known as carcinogens. Particular
substances have been linked to specific types of cancer. Tobacco smoking is
associated with many forms of cancer, and causes 90% of lung cancer.
Many mutagens are also carcinogens, but some carcinogens are not
mutagens. Alcohol is an example of a chemical carcinogen that is not a mutagen. In
Western Europe 10% of cancers in males and 3% of cancers in females are
attributed to alcohol.
Decades of research has demonstrated the link between tobacco use and
cancer in the lung, larynx, head, neck, stomach, bladder, kidney,
esophagus and pancreas. Tobacco smoke contains over fifty known carcinogens,
including nitrosamines and polycyclic aromatic hydrocarbons. Tobacco is
responsible for about one in three of all cancer deaths in the developed world, and
about one in five worldwide. Lung cancer death rates in the United States have
mirrored smoking patterns, with increases in smoking followed by dramatic
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increases in lung cancer death rates and, more recently, decreases in smoking rates
since the 1950s followed by decreases in lung cancer death rates in men since
1990. However, the numbers of smokers worldwide is still rising, leading to what
some organizations have described as the tobacco epidemic.
Cancer related to one's occupation is believed to represent between 2–20% of
all cases. Every year, at least 200,000 people die worldwide from cancer related to
their workplace. Most cancer deaths caused by occupational risk factors occur in the
developed world. It is estimated that approximately 20,000 cancer deaths and 40,000
new cases of cancer each year in the U.S. are attributable to occupation. Millions of
workers run the risk of developing cancers such as lung
cancer and mesothelioma from inhaling asbestos fibers and tobacco smoke,
or leukemia from exposure to benzene at their workplaces.
DIET
Diet, physical inactivity, and obesity are related to approximately 30–35% of
cancer cases. In the United States excess body weight is associated with the
development of many types of cancer and is a factor in 14–20% of all cancer
deaths. Physical inactivity is believed to contribute to cancer risk not only through
its effect on body weight but also through negative effects on immune
system and endocrine system.
Diets that are low in vegetables, fruits and whole grains, and high in
processed or red meats are linked with a number of cancers. A high salt diet is linked
to gastric cancer, aflatoxin B1, a frequent food contaminate, with liver cancer,
and Betel nut chewing with oral cancer. This may partly explain differences in
cancer incidence in different countries for example gastric cancer is more common
in Japan with its high salt diet and colon cancer is more common in the United
States. Immigrants develop the risk of their new country, often within one
generation, suggesting a substantial link between diet and cancer.
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INFECTION
Worldwide approximately 18% of cancers are related to infectious
diseases. This proportion varies in different regions of the world from a high of 25%
in Africa to less than 10% in the developed world. Viruses are the usual infectious
agents that cause cancer but bacteria and parasites may also have an effect.
A virus that can cause cancer is called an oncovirus. These include human
papillomavirus (cervical carcinoma), Epstein-Barr virus (B-cell lymphoproliferative
disease and nasopharyngeal carcinoma), Kaposi's sarcoma herpesvirus (Kaposi's
Sarcoma and primary effusion lymphomas), hepatitis B and hepatitis C viruses
(hepatocellular carcinoma), and Human T-cell leukemia virus-1 (T-cell leukemias).
Bacterial infection may also increase the risk of cancer, as seen in Helicobacter
pylori-induced gastric carcinoma. Parasitic infections strongly associated with
cancer include Schistosoma haematobium (squamous cell carcinoma of the bladder)
and the liver flukes, Opisthorchis viverrini and Clonorchis
sinensis(cholangiocarcinoma).
RADIATION
Up to 10% of invasive cancers are related to radiation exposure, including
both ionizing radiation and non-ionizing radiation. Additionally, the vast majority of
non-invasive cancers are non-melanoma skin cancers caused by non-
ionizing ultraviolet radiation.
Sources of ionizing radiation include medical imaging, and radon gas.
Radiation can cause cancer in most parts of the body, in all animals, and at any age,
although radiation-induced solid tumors usually take 10–15 years, and can take up to
40 years, to become clinically manifest, and radiation-induced leukemias typically
require 2–10 years to appear. Some people, such as those with nevoid basal cell
carcinoma syndrome or retinoblastoma, are more susceptible than average to
developing cancer from radiation exposure. Children and adolescents are twice as
likely to develop radiation-induced leukemia as adults; radiation exposure before
birth has ten times the effect. Ionizing radiation is not a particularly strong mutagen.
Residential exposure to radon gas, for example, has similar cancer risks as passive
smoking. Low-dose exposures, such as living near a nuclear power plant, are
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generally believed to have no or very little effect on cancer development. Radiation
is a more potent source of cancer when it is combined with other cancer-causing
agents, such as radon gas exposure plus smoking tobacco.
Unlike chemical or physical triggers for cancer, ionizing radiation hits
molecules within cells randomly. If it happens to strike a chromosome, it can break
the chromosome, result in an abnormal number of chromosomes, inactivate one or
more genes in the part of the chromosome that it hit, delete parts of the DNA
sequence, cause chromosome translocations, or cause other types of chromosome
abnormalities. Major damage normally results in the cell dying, but smaller damage
may leave a stable, partly functional cell that may be capable of proliferating and
developing into cancer, especially if tumor suppressor genes were damaged by the
radiation. Three independent stages appear to be involved in the creation of cancer
with ionizing radiation: morphological changes to the cell, acquiring cellular
immortality (losing normal, life-limiting cell regulatory processes), and adaptations
that favor formation of a tumor. Even if the radiation particle does not strike the
DNA directly, it triggers responses from cells that indirectly increase the likelihood
of mutations.
Medical use of ionizing radiation is a growing source of radiation-induced
cancers. Ionizing radiation may be used to treat other cancers, but this may, in some
cases, induce a second form of cancer. It is also used in some kinds of medical
imaging. One report estimates that approximately 29,000 future cancers could be
related to the approximately 70 million CT scans performed in the US in 2007. It is
estimated that 0.4% of cancers in 2007 in the United States are due to CTs
performed in the past and that this may increase to as high as 1.5–2% with rates of
CT usage during this same time period.
Prolonged exposure to ultraviolet radiation from the sun can lead
to melanoma and other skin malignancies. Clear evidence establishes ultraviolet
radiation, especially the non-ionizing medium wave UVB, as the cause of most non-
melanoma skin cancers, which are the most common forms of cancer in the world.
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HEREDITY
The vast majority of cancers are non-hereditary ("sporadic
cancers"). Hereditary cancers are primarily caused by an inherited genetic defect.
Less than 0.3% of the population carriers of a genetic mutation which has a large
effect on cancer risk and these cause less than 3–10% of all cancer. Some of
these syndromes include: certain inherited mutations in the
genes BRCA1 and BRCA2 with a more than 75% risk of breast cancer and ovarian
cancer, and hereditary nonpolyposis colorectal cancer (HNPCC or Lynch syndrome)
which is present in about 3% of people with colorectal cancer, among others.
PHYSICAL AGENTS
Some substances cause cancer primarily through their physical, rather than
chemical, effects on cells.
A prominent example of this is prolonged exposure to asbestos, naturally
occurring mineral fibers which are a major cause of mesothelioma, a type of lung
cancer. Other substances in this category, including both naturally occurring and
synthetic asbestos-like fibers such as wollastonite, attapulgite, glass wool, and rock
wool, are believed to have similar effects.
Nonfibrous particulate materials that cause cancer include powdered
metallic cobalt and nickel, and crystalline silica (quartz, cristobalite, and tridymite).
Usually, physical carcinogens must get inside the body (such as through
inhaling tiny pieces) and require years of exposure to develop cancer.
Physical trauma resulting in cancer is relatively rare. Claims that breaking
bone resulted in bone cancer, for example, have never been proven. Similarly,
physical trauma is not accepted as a cause for cervical cancer, breast cancer, or brain
cancer.
One accepted source is frequent, long-term application of hot objects to the
body. It is possible that repeated burns on the same part of the body, such as those
produced by kanger and kairo heaters (charcoal hand warmers), may produce skin
cancer, especially if carcinogenic chemicals are also present. Frequently drinking
scalding hot tea may produce esophageal cancer.
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Generally, it is believed that the cancer arises, or a pre-existing cancer is
encouraged, during the process of repairing the trauma, rather than the cancer being
caused directly by the trauma. However, repeated injuries to the same tissues might
promote excessive cell proliferation, which could then increase the odds of a
cancerous mutation. There is no evidence that inflammation itself causes cancer.
HORMONES
Some hormones play a role in the development of cancer by promoting cell
proliferation. Hormones are important agents in sex-related cancers such as cancer
of the breast, endometrial, prostate, ovary, and testis, and also of thyroid
cancer and bone cancer.
An individual's hormone levels are mostly determined genetically, so this
may at least partly explains the presence of some cancers that run in families that do
not seem to have any cancer-causing genes. For example, the daughters of women
who have breast cancer have significantly higher levels
of estrogen and progesterone than the daughters of women without breast cancer.
These higher hormone levels may explain why these women have higher risk of
breast cancer, even in the absence of a breast-cancer gene. Similarly, men of African
ancestry have significantly higher levels of testosterone than men of European
ancestry, and have a correspondingly much higher level of prostate cancer. Men of
Asian ancestry, with the lowest levels of testosterone-activating androstanediol
glucuronide, have the lowest levels of prostate cancer.
However, non-genetic factors are also relevant: obese people have higher
levels of some hormones associated with cancer and a higher rate of those
cancers. Women who take hormone replacement therapy have a higher risk of
developing cancers associated with those hormones. On the other hand, people who
exercise far more than average have lower levels of these hormones, and lower risk
of cancer. Osteosarcoma may be promoted by growth hormones. Some treatments
and prevention approaches leverage this cause by artificially reducing hormone
levels, and thus discouraging hormone-sensitive cancers. (Kinzler et al., 2002)
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OTHER
Excepting the rare transmissions that occur with pregnancies and only a
marginal few organ donors, cancer is generally not a transmissible disease. The main
reason for this is tissue graft rejection caused by MHC incompatibility. In humans
and other vertebrates, the immune system uses MHC antigens to differentiate
between "self" and "non-self" cells because these antigens are different from person
to person. When non-self antigens are encountered, the immune system reacts
against the appropriate cell. Such reactions may protect against tumour cell
engraftment by eliminating implanted cells. In the United States, approximately
3,500 pregnant women have a malignancy annually, and transplacental transmission
of acute leukaemia, lymphoma, melanoma and carcinoma from mother to fetus has
been observed. The development of donor-derived tumors from organ transplants is
exceedingly rare. The main cause of organ transplant associated tumors seems to be
malignant melanoma, that was undetected at the time of organ harvest. Cancer from
one organism will usually grow in another organism of that species, as long as they
share the same histocompatibility genes, proven using mice; however this would
never happen in a real-world setting except as described above.
In non-humans, a few types of transmissible cancer have been described,
wherein the cancer spreads between animals by transmission of the tumor cells
themselves. This phenomenon is seen in dogs with Sticker's sarcoma, also known as
canine transmissible venereal tumor, as well as devil facial tumour
disease in Tasmanian devils.
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PATHOPHYSIOLOGY
Cancer is fundamentally a disease of failure of regulation of tissue growth. In
order for a normal cell to transform into a cancer cell, the genes which regulate cell
growth and differentiation must be altered.
The affected genes are divided into two broad categories. Oncogenes are
genes which promote cell growth and reproduction. Tumor suppressor genes are
genes which inhibit cell division and survival. Malignant transformation can occur
through the formation of novel oncogenes, the inappropriate over-expression of
normal oncogenes, or by the under-expression or disabling of tumor suppressor
genes. Typically, changes in many genes are required to transform a normal cell into
a cancer cell.
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Genetic changes can occur at different levels and by different mechanisms.
The gain or loss of an entire chromosome can occur through errors in mitosis. More
common are mutations, which are changes in the nucleotide sequence of genomic
DNA.
Large-scale mutations involve the deletion or gain of a portion of a
chromosome. Genomic amplification occurs when a cell gains many copies (often
20 or more) of a small chromosomal locus, usually containing one or more
oncogenes and adjacent genetic material. Translocation occurs when two separate
chromosomal regions become abnormally fused, often at a characteristic location. A
well-known example of this is the Philadelphia chromosome, or translocation of
chromosomes 9 and 22, which occurs in chronic myelogenous leukemia, and results
in production of the BCR-abl fusion protein, an oncogenic tyrosine kinase.
Small-scale mutations include point mutations, deletions, and insertions,
which may occur in the promoter region of a gene and affect its expression, or may
occur in the gene's coding sequence and alter the function or stability of
its protein product. Disruption of a single gene may also result from integration of
genomic material from a DNA virus or retrovirus, and resulting in the expression
of viral oncogenes in the affected cell and its descendants.
Replication of the enormous amount of data contained within the DNA of
living cells will probabilistically result in some errors (mutations). Complex error
correction and prevention is built into the process, and safeguards the cell against
cancer. If significant error occurs, the damaged cell can "self-destruct" through
programmed cell death, termed apoptosis. If the error control processes fail, then the
mutations will survive and be passed along to daughter cells.
Some environments make errors more likely to arise and propagate. Such
environments can include the presence of disruptive substances called carcinogens,
repeated physical injury, heat, ionising radiation, or hypoxia. . (Kim et al., 2006)
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The errors which cause cancer are self-amplifying and compounding, for example:
 A mutation in the error-correcting machinery of a cell might cause that cell and
its children to accumulate errors more rapidly.
 A further mutation in an oncogene might cause the cell to reproduce more
rapidly and more frequently than its normal counterparts.
 A further mutation may cause loss of a tumour suppressor gene, disrupting the
apoptosis signaling pathway and resulting in the cell becoming immortal.
 A further mutation in signaling machinery of the cell might send error-causing
signals to nearby cells.
The transformation of normal cell into cancer is akin to a chain
reaction caused by initial errors, which compound into more severe errors, each
progressively allowing the cell to escape the controls that limit normal tissue growth.
This rebellion-like scenario becomes an undesirable survival of the fittest, where the
driving forces of evolution work against the body's design and enforcement of order.
Once cancer has begun to develop, this ongoing process, termed clonal
evolution drives progression towards more invasive stages. (Croce, 2008)
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DIAGNOSIS
Most cancers are initially recognized either because of the appearance of
signs or symptoms or through screening. Neither of these lead to a definitive
diagnosis, which requires the examination of a tissue sample by a pathologist.
People with suspected cancer are investigated with medical tests. These commonly
include blood tests, X-rays, CT scans and endoscopy.
CLASSIFICATION
Cancers are classified by the type of cell that the tumor cells resemble and
therefore presumed to be the origin of the tumor. These types include:
 Carcinoma: Cancers derived from epithelial cells. This group includes many of
the most common cancers, particularly in the aged, and include nearly all those
developing in the breast, prostate, lung, pancreas, and colon.
 Sarcoma: Cancers arising from connective tissue (i.e. bone, cartilage, fat, nerve),
each of which develop from cells originating in mesenchymal cells outside the
bone marrow.
 Lymphoma and leukemia: These two classes of cancer arise from hematopoietic
(blood-forming) cells that leave the marrow and tend to mature in the lymph
nodes and blood, respectively.
 Germ cell tumor: Cancers derived from pluripotent cells, most often presenting
in the testicle or the ovary (seminoma and dysgerminoma, respectively).
 Blastoma: Cancers derived from immature "precursor" cells or embryonic tissue.
These are also most common in children. (Kinzler et al., 2002)
Cancers are usually named using -carcinoma, -sarcoma or -blastoma as a suffix,
with the Latin or Greek word for the organ or tissue of origin as the root. For
example, cancers of the liver parenchyma arising from malignant epithelial cells is
called hepatocarcinoma, while a malignancy arising from primitive liver precursor
cells is called a hepatoblastoma, and a cancer arising from fat cells is called
a liposarcoma.
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For some common cancers, the English organ name is used. For example, the
most common type of breast cancer is called ductal carcinoma of the breast. Here,
the adjective ductal refers to the appearance of the cancer under the microscope,
which suggests that it has originated in the milk ducts.
Benign tumors (which are not cancers) are named using -oma as a suffix with
the organ name as the root. For example, a benign tumor of smooth muscle cells is
called a leiomyoma (the common name of this frequently occurring benign tumor in
the uterus is fibroid). Confusingly, some types of cancer also use the -oma suffix,
examples including melanoma andseminoma.
Some types of cancer are named for the size and shape of the cells under a
microscope, such as giant cell carcinoma, spindle cell carcinoma, and small cell
carcinoma.
PATHOLOGY
The tissue diagnosis given by the pathologist indicates the type of cell that is
proliferating, its histological grade, genetic abnormalities, and other features of the
tumor. Together, this information is useful to evaluate the prognosis of the patient
and to choose the best treatment. Cytogenetics and immuno histochemistry are other
types of testing that the pathologist may perform on the tissue specimen. These tests
may provide information about the molecular changes (such as mutations, fusion
genes, and numerical chromosome changes) that has happened in the cancer cells,
and may thus also indicate the future behavior of the cancer (prognosis) and best
treatment.
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MANAGEMENT
Many management options for cancer exist with the primary ones
including: surgery, chemotherapy, radiation therapy, and palliative care. Which
treatments are used depends upon the type, location and grade of the cancer as well
as the person's health and wishes.
SURGERY
Surgery is the primary method of treatment of most isolated solid cancers
and may play a role in palliation and prolongation of survival. It is typically an
important part of making the definitive diagnosis and staging the tumor as biopsies
are usually required. In localized cancer surgery typically attempts to remove the
entire mass along with, in certain cases, the lymph nodes in the area. For some types
of cancer this is all that is needed for a good outcome.
CHEMOTHERAPY
Chemotherapy in addition to surgery has proven useful in a number of
different cancer types including: breast cancer, colorectal cancer, pancreatic
cancer, osteogenic sarcoma, testicular cancer, ovarian cancer, and certain lung
cancers.[81] The effectiveness of chemotherapy is often limited by toxicity to other
tissues in the body.
RADIATION
Radiation therapy involves the use of ionizing radiation in an attempt to
either cure or improve the symptoms of cancer. It is used in about half of all cases
and the radiation can be from either internal sources in the form of brachytherapy or
external sources. Radiation is typically used in addition to surgery and or
chemotherapy but for certain types of cancer such as early head and neck
cancer may be used alone. For painful bone metastasis it has been found to be
effective in about 70% of people.
Chapter 1 Introduction
Dept. of Pharmacology 18 JKK Nattraja College of Pharmacy
ALTERNATIVE TREATMENTS
Complementary and alternative cancer treatments are a diverse group of
health care systems, practices, and products that are not part of conventional
medicine and have not been shown to be effective. "Complementary medicine"
refers to methods and substances used along with conventional medicine, while
"alternative medicine" refers to compounds used instead of conventional
medicine. Most complementary and alternative medicines for cancer have not been
rigorously studied or tested. Some alternative treatments have been investigated and
shown to be ineffective but still continue to be marketed and promoted.
PALLIATIVE CARE
Palliative care is an approach to symptom management that aims to reduce
the physical, emotional, spiritual, and psycho-social distress experienced by people
with cancer. Unlike treatment that is aimed at directly killing cancer cells, the
primary goal of palliative care is to make the person feel better.
Palliative care is often confused with hospice and therefore only involved
when people approach end of life. Like hospice care, palliative care attempts to help
the person cope with the immediate needs and to increase the person's comfort.
Unlike hospice care, palliative care does not require people to stop treatment aimed
at prolonging their lives or curing the cancer. (Astin et al., 1998)
Multiple national medical guidelines recommend early palliative care for
people whose cancer has produced distressing symptoms (pain, shortness of breath,
fatigue, nausea) or who need help coping with their illness. In people who have
metastatic disease when first diagnosed, oncologists should consider a palliative care
consult immediately. Additionally, an oncologist should consider a palliative care
consult in any patient they feel has a prognosis of less than 12 months even if
continuing aggressive treatment.
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PROGNOSIS
Cancer has a reputation as a deadly disease. Taken as a whole, about half of
people receiving treatment for invasive cancer (excluding carcinoma in situ and non-
melanoma skin cancers) die from cancer or its treatment. Survival is worse in the
developing world. However, the survival rates vary dramatically by type of cancer,
with the range running from basically all people surviving to almost no one
surviving. As of 2012, lung cancer is by far the most lethal type of cancer for men;
breast cancer is the second-leading cause of cancer-related deaths for women
(approximately 23 cases out of every 100,000 women), followed by colon and
rectum cancer (15 out of every 100,000). Those who survive cancer are at increased
risk of developing a second primary cancer at about twice the rate of those never
diagnosed with cancer. The increased risk is believed to be primarily due to the same
risk factors that produced the first cancer, partly due to the treatment for the first
cancer, and potentially related to better compliance with screening.
Predicting either short-term or long-term survival is difficult and depends on
many factors. The most important factors are the particular kind of cancer and the
patient's age and overall health. People who are frail with many other health
problems have lower survival rates than otherwise healthy people. A centenarian is
unlikely to survive for five years even if the treatment is successful. People who
report a higher quality of life tend to survive longer. People with lower quality of
life may be affected by major depressive disorder and other complications from
cancer treatment and/or disease progression that both impairs their quality of life and
reduces their quantity of life. Additionally, patients with worse prognoses may be
depressed or report a lower quality of life directly because they correctly perceive
that their condition is likely to be fatal.
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According to the National Cancer Institute in 2010, the most common
cancers (excluding non-melanoma skin cancers) are listed below.
Cancer type Estimated new cases Estimated deaths
Bladder 70,530 14,680
Breast (female-male) 207,090-1,970 39,840-390
Colon and rectal (combined) 142,570 51,370
Endometrial 43,470 7,950
Kidney (renal cell) 53,581 11,997
Leukemia 43,050 21,840
Lung (including bronchus) 222,520 157,300
Melanoma 68,130 8,700
Non-Hodgkin lymphoma 65,540 20,210
Pancreatic 43,140 36,800
Prostate 217,730 32,050
Thyroid 44,670 1,690
Some other cancers include brain cancer, hodgkin’s lymphoma, testicular
cancer, liver cancer, uterine cancer.
The three most common cancers in men, women and children are as follows:
 Men: Prostate, lung, and colorectal.
 Women: Breast, colorectal, and lung.
 Children: Leukemia, brain tumours, and lymphoma. (Jermal et al., 2011)
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PREVENTION
Cancer prevention is defined as active measures to decrease the risk of
cancer.[43] The vast majority of cancer risk factors are due to environmental
(including lifestyle) factors, and many of these factors are controllable. Thus, cancer
is largely considered a preventable disease. Greater than 30% of cancer is considered
preventable by avoiding risk factors including: tobacco, overweight / obesity, an
insufficient diet, physical inactivity, alcohol, sexually transmitted infections, and air
pollution. Not all environmental causes can be prevented completely such as
naturally occurring background radiation.
DIETARY
While many dietary recommendations have been proposed to reduce the risk
of cancer, few have significant supporting scientific evidence. The primary dietary
factors that increase risk are obesity and alcohol consumption; with a diet low in
fruits and vegetables and high in red meat being implicated but not
confirmed. Consumption of coffee is associated with a reduced risk of liver
cancer. Studies have linked consumption of red or processed meat to an increased
risk of breast cancer, colon cancer, and pancreatic cancer, a phenomenon which
could be due to the presence of carcinogens in foods cooked at high
temperatures. Thus dietary recommendation for cancer prevention typically include:
"mainly vegetables, fruit, whole grain and fish and a reduced intake of red meat,
animal fat and refined sugar."
MEDICATION
The concept that medications can be used to prevent cancer is attractive, and
evidence supports their use in a few defined circumstances. In the general
population NSAIDs reduce the risk of colorectal cancer however due to the
cardiovascular and gastrointestinal side effects they cause overall harm when used
for prevention. Aspirin has been found to reduce the risk of death from cancer by
about 7%.COX-2 inhibitor may decrease the rate of polyp formation in people
with familial adenomatous polyposis however are associated with the same adverse
effects as NSAIDs. Daily use of tamoxifen or raloxifene has been demonstrated to
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reduce the risk of developing breast cancer in high-risk women. The benefit verses
harm for 5-alpha-reductase inhibitor such as finasteride is not clear.
Vitamins have not been found to be effective at preventing cancer, although
low blood levels of vitamin D are correlated with increased cancer risk. Whether this
relationship is causal and vitamin D supplementation is protective is not
determined. Beta-carotene supplementation has been found to increase lung
cancer rates in those who are high risk. Folic acid supplementation has not been
found effective in preventing colon cancer and may increase colon polyps.[63]
VACCINATION
Vaccines have been developed that prevent some infection by some
viruses. Human papillomavirus vaccine (Gardasil and Cervarix) decreases the risk of
developing cervical cancer. The hepatitis B vaccine prevents infection with hepatitis
B virus and thus decreases the risk of liver cancer. ( Thum et. al. 2007)
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HOW CELLS DIE: APOPTOSIS AND OTHER
Cell death is an essential part of normal development and continues into
adulthood. The human body, for instance, is composed of approximately 1014 cells.
Every day billions of  cells  die an altruistic death in order to secure the functionality
of the whole organism.  Thus, we remain the same size only because cell division
exactly balances cell death.
During development, cell death helps sculpt organs or separate fingers and
toes. It also  eliminates structures that once served a function but are no longer
needed, such as the  tail of a tadpole during amphibian metamorphosis. Most of the
neurons die during  development before having any chance to function in the
nervous system. Cell death also eliminates most newly formed lymphocytes,
especially those that are useless or dangerous, by targeting self-antigens.
Neutrophils, for instance, are produced continuously in  the bone marrow, but the
vast majority die within a few days. This apparently futile cycle of cell proliferation
and cell death serves to maintain a supply of cells that can be readily  mobilized
when needed .
As cell death is intimately linked to tissue homeostasis, its disruption has, not
surprisingly, been implicated in numerous pathological conditions. A reasonable
estimate is  that either too little or too much cell death contributes to approximately
half of all  medical illnesses, for many of which no adequate therapy exists.
Abnormalities in cell  death regulation can be a significant component of diseases
such as cancer, autoimmune syndromes, AIDS, ischemia, liver diseases and
neurodegenerative disorders including  Parkinson’s and Alzheimer’s disease .
Consequently, considerable interest has emerged in devising therapeutic strategies
aimed at modulating cellular life-and-death decisions.
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TERMINOLOGY OF CELL DEATH
Apoptosis, also termed type I cell death, is defined by characteristic changes
in the  nuclear morphology, including chromatin condensation and fragmentation,
overall cell shrinkage, blebbing of the plasma membrane and formation of apoptotic
bodies that contain nuclear or cytoplasmic material
Autophagic cell death, also known as type II cell death, is characterized by a
massive accumulation of double-membrane containing vacuoles known as
autophagosomes, which subsequently fuse with lysosome vacuoles.
Type III cell death, better known as necrosis, is often defined in a negative
manner as death lacking the characteristics of the type I and type II processes.
Distinction of different cell death forms is not only relevant for semantic
reasons, but can also have important clinical implications when considering the
potential therapeutic targeting of cell death processes. Nevertheless, in some
conditions these distinct cell modes may only be the extremes, and there are
numerous examples in which cell death demonstrates a continuum of intermediate
features, for instance of both apoptosis and necrosis..
Furthermore, in some cases it is the cell type or the nature and duration of
cellular injury that determine whether cells die by apoptosis, necrosis or other
default mechanisms. At low doses, a variety of harmful stimuli such as radiation,
hypoxia and anticancer drugs can induce apoptosis, but the same stimuli can result
in necrosis at higher  doses. Therefore, in many situations cell death may not occur
as a clear-cut and paradigmatic form of cell death.
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APOPTOSIS
Apoptosis occurs in a well-choreographed sequence of morphological events.
This process usually starts with the blebbing of the plasma membrane, which breaks
up into membrane-enclosed particles, termed apoptotic bodies, containing intact
organelles as well as portions of the nucleus. In fact the word ‘apoptosis’ comes
from the ancient Greek, meaning ‘falling off ’ (of petals from a flower) and refers to
the morphological feature of the formation of apoptotic bodies . These apoptotic
bodies are rapidly  recognized, ingested and eaten by professional phagocytes or
neighboring cells. Under physiological conditions certain modifications occur in the
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plasma membrane which function as ‘eat-me’ signals and enable the apoptotic
bodies to be recognized by phagocytic cells. Since the apoptotic bodies are
surrounded by an intact plasma membrane, apoptosis usually occurs without any
leakage of cellular contents and therefore without provoking an inflammatory
response. Moreover, the engulfment of apoptotic cells by macrophages triggers the
production of anti-inflammatory cytokines.
Because apoptotic cells are eaten and digested so quickly, there are usually
few dead cells to be seen in tissue sections, even when large numbers of cells have
died. This probably explains why apoptosis was neglected by pathologists for a long
time. Looking inside the cell, one of the most noticeable features of apoptosis is the
condensation of the nucleus and its fragmentation into smaller pieces, a highly
distinctive event that is not seen in other forms of cell death. Another defining
feature is the extensive hydrolysis of nuclear DNA into internucleosomal fragments .
Apoptosis is the major cell death pathway for removing unwanted and
harmful cells in a clean or silent manner during embryonic development, tissue
homeostasis and immune regulation. In addition, most anti-cancer therapies rely on
the activation of apoptotic pathways. As the alterations of apoptosis are stereotypical
and similar in all cell types irrespective of the death stimulus, the biochemical
mechanisms underlying these changes also follow a similar built-in program. In
nematodes, insects and human cells, most, if not all, morphological alterations of
apoptosis are mediated by the activation of an evolutionarily conserved and unique
class of intracellular proteases known as caspases .
AUTOPHAGY
Like apoptosis, autophagy is a highly conserved and genetically controlled
process involving a cascade of molecular events. Autophagy (meaning self-eating) is
classically activated in response to nutrient starvation, but is also observed during
development, differentiation and various forms of environmental stress. In addition,
defective autophagy underlies a number of pathological conditions, including
myopa-thies, neurodegenerative diseases, liver diseases, and some forms of cancer .
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Autophagy is a major catabolic mechanism by which long-lived proteins and
organelle components are directed to lysosomes and recycled in order to maintain
energy and protein synthesis. It is characterized by the appearance of numerous
cytosolic vacuole-like structures known as autophagosomes, which are formed by
the assembly of double-layered, membrane-bound structures of still largely
undefined origin. The autophago-somes encapsulate cytosolic materials and
subsequently fuse with lysosomes, which causes the autophagosomal contents to
degrade .
Although the role of the autophagic process in protein and organelle
degradation, and inprotection during nutrient starvation is readily accepted, its
function in programmed cell death is controversial . This is partly because the term
‘autophagic cell death’ hasbeen applied to two distinct observations: cell death
associated with autophagy and cell death through autophagy.
Under normal physiological conditions autophagy occurs at low basal levels,
contribut-ing to the turnover of cytoplasmic components and promoting cell
adaptation and survival during stress, e.g. starvation. Excess autophagy, on the other
hand, leads to autophagic cell death. Interestingly, in cells deficient for apoptosis,
apoptotic signals can trigger massive autophagy and cell death, which is prevented
by the inhibition of autophagosome formation. Thus, a complex relationship also
exists between autophagy and apoptosis, in that autophagy can both promote and
inhibit apoptotic cell death. Interestingly, some of the regulators of apoptosis also
interfere with autophagic processes . At present, it would seem that, while the
predominant function of autophagy is to promote cell survival, extended autophagy
will result in autophagic cell death. Clearly, more work is needed to elucidate the
role of autophagy as a cell death mechanism and the complex crosstalk with other
cell death pathways.
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NECROSIS
Necrotic cell death is often defined negatively as a form of cell death that
lacks signs of apoptosis or autophagy. Necrotic cells typically show cytoplasmic
swelling and vacuolation, rupture of the plasma membrane, dilation of organelles
(mitochondria, endoplasmic reticulum and Golgi apparatus), as well as moderate
chromatin condensation. When cells swell and burst they spill their contents over
their neighbors and elicit a damaging inflammatory response.
Necrosis is usually considered to be an uncontrolled and accidental cell death
which, unlike apoptosis, is not energy-dependent. Biochemically, most prominent
features include massive energy depletion, the formation of reactive oxygen species
and the activation of non-apoptotic proteases. All these events result in a loss of
function of homeostatic ion pumps and damage to membrane lipids with cell
membrane swelling and rupture
Furthermore, during necrosis a substantial rise in intracellular calcium is
observed. The elevated calcium levels in the cytosol trigger mitochondrial calcium
overload, leading to depolarization of the inner mitochondrial membrane and a shut-
down of ATP production . While depletion of ATP impedes the function of
membrane channels, increased calcium activates calcium-dependent proteases, e.g.
calpains. Calcium fluxes, ATP depletion and oxidative stress involve complex and
interactive feedback loops that self-amplify and potentiate each other, leading to
exaggerated cell death. Such processes are most relevant under conditions of
excessive trauma and ischemia-reperfusion. Necrosis, however, can also be observed
in response to death receptor activation or chemotherapy, conditions that were
originally believed to mediate cell death exclusively via apoptosis.
In addition, the inhibition of specific proteins involved in regulating
apoptosis or autophagy can switch the type of cell death to necrosis. Finally,
secondary or post-apop-totic necrosis occurs when massive apoptosis overwhelms
the scavenging activity of phagocytes, thereby resulting in leakage of the cell
contents with induction of inflamma-tory responses.
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There is increasing evidence that necrosis is more tightly regulated than
previously thought and underlies a genetic control that might be relevant in multiple
physiological and pathological scenarios . Necrosis might therefore serve as a
backup cell death mechanism when apoptosis or autophagic cell death fails.
TERMINOLOGY OF CELL PROLIFERATION AND VIABILITY
Rapid and accurate assessment of viable cell number and cell proliferation is
an impor- tant requirement in many experimental situations involving in vitro and in
vivo studies. Examples of where determination of cell number is useful include the
analysis of growth factor activity, serum batch testing, drug screening, and the
determination of the cytostatic potential of anti-cancer compounds in toxicology
testing. In such toxicological studies, in vitro testing techniques are very useful to
evaluate the cytotoxic, mutagenic, and carcinogenic effects of chemical compounds
on human cells.
Usually, one of two parameters is used to measure the health of cells: cell
viability or cell proliferation. In almost all cases, these parameters are measured by
assaying for “vital functions” that are characteristic of healthy cells.
CELL VIABILITY
Cell viability can be defined as the number of healthy cells in a sample.
Whether the cells are actively dividing or are quiescent is not distinguished. Cell
viability assays are often useful when non-dividing cells (such as primary cells) are
isolated and maintained in culture to determine optimal culture conditions for cell
populations.
The most straightforward method for determining viable cell number is a
direct   counting of the cells in a hemocytometer. Sometimes viable cells are scored
based on morphology alone; however, it is more helpful to stain the cells with a dye
such as trypan blue. In this case, viability is measured by the ability of cells with
uncompromised  membrane integrity to exclude the dye.
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Alternatively, metabolic activity can be assayed as an indication of cell
viability. Usually metabolic activity is measured in populations of cells by
incubating the cells with a tetrazolium salt (MTT, XTT, WST-1) that is cleaved into
a colored formazan product by metabolic activity.
CELL PROLIFERATION
Cell proliferation is the measurement of the number of cells that are dividing
in a culture. One way of measuring this parameter is by performing clonogenic
assays. In these assays, a defined number of cells are plated onto the appropriate
matrix and the number of colonies that are formed after a period of growth are
enumerated. Drawbacks to this type of technique are that it is tedious and it is not
practical for large numbers of samples. In addition, if cells divide only a few times
and then become quiescent, colonies may be too small to be counted and the number
of dividing cells may be underestimated. Alternatively, growth curves could be
established, which is also time-consuming and laborious.
Another way to analyze cell proliferation is the measurement of DNA
synthesis as a marker for proliferation. In these assays, labeled DNA precursors (3H-
thymidine or  bromodeoxyuridine) are added to cells and their incorporation into
DNA is quantified after incubation. The amount of labeled precursor incorporated
into DNA is quantified either by measuring the total amount of labeled DNA in a
population, or by detecting the labeled nuclei microscopically. Incorporation of the
labeled precursor into DNA is directly proportional to the amount of cell division
occurring in the culture.
Cell proliferation can also be measured using more indirect parameters. In
these techniques, molecules that regulate the cell cycle are measured either by their
activity (e.g., CDK kinase assays) or by quantifying their amounts (e.g., Western
blots, ELISA, or immunohistochemistry).
Chapter 1 Introduction
Dept. of Pharmacology 31 JKK Nattraja College of Pharmacy
WHY THE PRESENT COMPOUNDS ARE TAKEN FOR ANTITUMOR
ACTIVITY?
Silibinin, a flavonone which is the class of flavonoid,  has shown the
prominent activity on the cancerous cell lines in previous studies. Silibinin has
shown the cell growth inhibition in cell culture by alteration of cell cycle
progression and inhibition of mitogenic and cell survival signaling. Silibinin also
found to inhibit the secretion of proangiogenic factor like Epidermal growth factor,
insulin growth factor, nuclear factor kappa β from tumor cell.
Genistein, a phytoestrogen which comes under the isoflavonone class of
flavonoids, has shown the inhibition of tyrosin kinase, and mostly the epidermal
derived growth factor. Which in turn destroys the cell signaling cascade and
proliferation of cells. Genistein has also shown the cytoprotective activity by
reducing the lipid peroxidaion.
This data supports the study of the silibinin and genistein to be tested
together for its cytotoxic activity in combined as it has never been performed on
breast and colon cell lines. The cytoproctive activity is assessed on the basis of trial
and error basis, because the compound silibinin hasn’t shown any kind of
cytoproctive activity until now.
So these compounds are choosan for the cytotoxic and cytoprotective activity
in single and in combination treatments.
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FLAVONOIDS
Flavonoids (or bioflavonoids) (from the Latin word flavus meaning yellow),
also collectively known as Vitamin P and citrin, are a class of plant secondary
metabolites or yellow pigments having a structure similar to that of flavones.
According to the IUPAC nomenclature they can be classified into:
 flavonoids, derived from 2-phenylchromen-4-one (2-phenyl-1, 4-benzopyrone)
structure (examples: quercetin, rutin).
 isoflavonoids, derived from 3-phenylchromen-4-one (3-phenyl-1,4-
benzopyrone) structure
 neoflavonoids, derived from 4-phenylcoumarine (4-phenyl-1,2-benzopyrone)
structure. (Flavanoids IUPAC compendium of chemical technology)
The three flavanoids classes above are all ketone-containing compounds, and
as such, are flavanoids and flavonol.
Flavonoids are the most important plant pigments for flower coloration
producing yellow or red/blue pigmentation in petals designed to attract pollinator
animals.
Flavonoids secreted by the root of their host plant help Rhizobia in the
infection stage of their symbiotic relationship with legumes like peas, beans, clover,
and soy.
In addition, some flavanoids have inhibitory activity against organisms that
cause plant disease e.g. Fusarium oxysporum.
1). SOURCES
Good sources of flavanoids include all citrus fruits, berries, ginkgo biloba,
onions (particularly red onion), parsley, pulses, tea (especially white and green tea),
red wine, sea buckthorn, and dark chocolate (with a cocoa content of seventy percent
or greater).
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Flavonoids (specifically flavanoids such as the catechins) are "the most
common group of polyphenolic compounds in the human diet and are found
ubiquitously in plants". Flavonols, the original bioflavonoids such as quercetin, are
also found ubiquitously, but in lesser quantities. (Brown, 1980), (Justesen et al.,
2001)
2). EFFECTS ON HUMAN HEALTH
Flavonoids might induce mechanisms that affect cancer cells and inhibit
tumor invasion. In preliminary studies, UCLA cancer researchers proposed that
smokers who ate foods containing certain flavanoids, such as catechins found in
strawberries and green and black teas, kaempferol from brussel sprouts and apples,
and quercetin from beans, onions and apples, may have reduced risk of obtaining
lung cancer.
The widespread distribution of flavonoids, their variety and their relatively
low toxicity compared to other active plant compounds (for instance alkaloids) mean
that many animals, including humans, ingest significant quantities in their diet.
Preliminary research indicates that flavonoids may modify allergens, viruses, and
carcinogens, and so may be biological "response modifiers". In vitro studies show
that flavonoids also have anti-allergic, anti-inflammatory, anti-microbial, anti-
cancer, and anti-diarrheal activities.
3). ANTIOXIDANT ACTIVITY INVITRO
Flavonoids (both flavonols and flavanols) are most commonly known for
their antioxidant activity. Additionally, at high experimental concentrations that
would not exist in vivo, the antioxidant abilities of flavanoids in vitro are stronger
than those of vitamin C & E.
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4). WHAT DO THEY DO?
As antioxidants, some flavanoids such as Quercetin protect LDL cholesterol
from oxidative damage.
The ability to limit inflammation gives the flavanoids their disease fighting
potential. They actively prevent the release of histamine in the body - this is the
agent responsible for most allergy symptoms like congestion.
Flavonoids also actively scavenge free radicals they tend to boost immune
system functioning and strengthen the blood vessels, thereby increasing the blood
flow.
Flavonoids exhibit potent anticancer effects, although the exact target of such
inhibition has not been definitely established, given the recent evidence for a
prominent role for reactive oxygen species (ROS) in carcinogenesis. It is tempting to
speculate that flavanoids inhibit carcinogenesis due to ROS scavenging. However
there have been a number of reports that directly contradict the potential role of
flavanoids as antioxidants/anticancer agents.
Flavonoid and related compound are effective in scavenging DPPH radical,
hydroxyl radical and in metal-chelating capacity. (Irfan khan 2011)
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SYNTHETIC DRUGS
Chemotherapy is the treatment of an ailment by chemicals especially by
killing micro-organisms and other malfunctions of the body.
The majority of chemotherapeutic drugs can be divided in to alkylating
agents, antimetabolites, anthracyclines, plant alkaloids, topoisomerase inhibitors,
and other antitumour agents. All of these drugs affect cell division or DNA synthesis
and function in some way.
Some newer agents do not directly interfere with DNA. These include
monoclonal antibodies and the new tyrosine kinase inhibitors e.g. imatinib mesylate
(Gleevec or Glivec), which directly targets a molecular abnormality in certain types
of cancer (chronic myelogenous leukemia, gastrointestinal stromal tumours). These
are examples of targeted therapies. (Tripathi, 2008)
In addition, some drugs that modulate tumor cell behaviour without directly
attacking those cells may be used. Hormone treatments fall into this category.
The different types of anti cancer agents used in chemotherapy are as follows
TYPES EXAMPLES
Alkylating agents Cisplatin, carboplatin and oxaliplatin
Anti-metabolites Purines - azathioprine, mercaptopurine
Pyramidines - 5-fluro uracil
Plant alkaloids Vincristine, vinblastine, vindesine,
vinorelbine
Podophyllotoxin Etopside, teniposide
Taxanes Docetaxel
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Topisomerase inhibitors Type 1 – irinotecan, topotecan
Type 2- amasacrine, etopside
Cytotoxic antibiotics Actinomycin, anthracyclines, belomycin
Others Hydroxyurea, procarbazine,
carboplatin,cisplatin
Drugs atering hormonal milieu Prednisolone, tamoxifen, hydroxyl
progesterone, fosfestrol, letrozole etc
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DIFFERENT METHODS FOR SCREENING OF NEW ANTICANCER
MOLECULES
The main aims of screening methods are
a. To test the ability of a compound to kill cancerous cells.
b. To discriminate between replicating and non-replicating cells.
c. To find the potency of the drug
d. Effectiveness of drug and specific site of action
The different methods of screening are
1. In-vitro methods
2. In-vivo methods
3. Cell line methods
1) INVITRO METHODS
In-vitro testing is preferred to in-vivo testing for testing the potential of
chemotherapeutic agents. In-vitro cultures can be cultivated under a controlled
environment (pH, temperature, humidity, oxygen/carbon dioxide balance etc)
resulting in homogenous batches of cells and reducing the mistakes.
Different types of in-vitro methods include
1. Tetrazolium salt assay(MTT)
2. Sulphorhodamine B assay
3. 3H thymidine uptake
4. Dye exclusion tests
5. Clonogenic assay
6. Cell counting assay
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These methods used to find different type of properties in culture cells and
thus used to detect the therapeutic effect of the drug and potency. These tests are
frequently used for screening of anti-cancer drugs:
S.NO ASSAY PROPERTIES
1 Tetrazolium salt assay(MTT) Enzymatic properties
2. Sulphorhodamine B assay Protein content and synthesis
3. 3H thymidine uptake DNA content and synthesis
4. Dye exclusion assay Membrane integrity of cell
5. Clonogenic assay Clonogenic properties
6. Cell counting assay Cell divison
2) INVIVO METHODS
The in-vivo testing is performed on animals to test the efficacy of the drug
on animals and to check the different parameters and compare them with the
standard.
1. DMBA induced mouse skin papillomas, rat mammary gland carcinogenesis,
oral cancer in hamster.
2. N-methyl, N- nitrosurea(NMU) induced rat mammary gland carcinogenesis.
3. NMU induced tracheal squamous cell carcinoma in hamster.
4. N, N diethyl nitrosamine (DEN) induced lung asenocarcinoma in hamster.
5. 1, 2 Dimethyl hydralazine (DMH) inducer colorectal adenocarcinoma in rat
and mouse.
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6. Azoxymethane (AOM) induced aberrant crypt foci in rats.
7. 1- Butyl-n-(4 hydroxy butyl)- nitrosamine induced bladder carcinoma in
mouse.
8. 2- Methylcholanthrene induced fibrosarcoma tumor in mouse.
9. 3-Methlcholanthrene induced skin tumours in mouse.
10. Benzopyrene induced fore stomach tumours in mouse.
In all these in-vivo methods the cancer is induced by some chemicals and
then the drug given by different routes and the efficacy measured and compared with
that of the standard drugs and thus the activity of the drug found out statistically.
3) CELL LINE METHODS
In this method of studies the cancer cells are directly induced into the animal
and propagated to induce cancer in the animals. The specified number of cells
inoculated in to a sensitive mouse strains and tumor developed rapidly as compared
to chemical carcinogen. It is much faster and less time consuming model than other
methods.
Different types of cell line techniques are
1. Hollow fiber technique.
2. Use of kenografts.
3. Nude mouse models.
4. New born rat model.
5. Transgenic mouse model.
6. DAL induced mouse model. (Gupta, 2008)
a) DAL (DALTON’S ASCITES LYMPHOMA) MOUSE MODEL
Ascites is excess fluid in the space between the tissues lining the abdomen
and abdominal organs (the peritoneal cavity). (Ascites medline plus, A service of
US national library of Medicine NIH national institute of health)
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Lymphomas are cancers that begin in the cells of the immune system
 It is a tumor cell line originally grown from a tumour of the thymus.
 It is propagated by growing as ascites tumour in mice.
 We can induce both ascites tumour and solid tumours using DAL
cells.
 It is easy to maintain in vivo.
 It is not an immunogenic.
The solid tumours were obtained by injecting the DAL cell lines
subcutaneously in to the mouse hind paw which gets increased in the mass and
becomes solid. This cannot be propagated like the ascites lymphoma.
b) MAINTENANCE OF CELL LINES:
Dalton’s lymphoma ascites tumour cell lines (DLA), originally obtained
from Amala Cancer Institute, Thrissur, Kerala and was propagated as transplantable
tumours in the peritoneal cavity of the mice were used for the study.
The tumour cell lines were maintained by serial peritoneal cavity I.P
transplantation in mice.
The fully grown tumour cell lines were aspirated from mouse peritoneal
cavity and mixed with PBS solution and mixed with tryphan blue solution. Taken
that suspended solution and counted the number of cells present in one ml by using
tryphan blue exclusion method and adjust the cell count to 1×106. Then PBS
solution was used and the cells were mixed well and were injected intraperitonially
in to a new healthy mouse and thus the cancer got developed with in 10-15days of
time.
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LITERATURE REVIEW
 Yun-Hee Shon et al., 2006 reported about the “Effective Chemopreventive
Activity of Genistein against Human Breast Cancer Cells”
“The author repored that on breast cancer cell lines Genistein inhibited cell
proliferation in estrogen receptor-positive (MCF-7) and estrogen receptor-
negative (MDA-MB-231) human breast carcinoma cell lines. Cytochrome
P450 (CYP) 1A1-mediated ethoxyresorufin O-deethylase (EROD) activity was
inhibited by genistein in a concentration-dependent manner. Genistein
significantly inhibited 12-O-tetradecanoylphorbol-13-acetate (TPA)-induced
cyclooxy-enase-2 activity and protein expression at the concentrations of 10 (p
< 0.05), 25 (p < 0.05) and 50 mM (p < 0.01). Inaddition, ornithine
decarboxylase (ODC) activity was reduced to 53.8 % of the control after 6 h
treatment with 50 mM genistein in MCF-7 breast cancer cells. These results
suggest that genistein could be of therapeutic value in preventing human breast
cancer.”
 Rana P. Singh et al., 2004 reported about the “Prostate Cancer Prevention by
Silibinin”
“The author reported that for PCA prevention, growth control and/or
treatment could be inhibition of epigenetic molecular events involved in PCA
growth, progression and angiogenesis. In this regard, silibinin/silymarin
(silibinin is  the  major  active compound in silymarin) has shown promising
efficacy. Our extensive studies with silibinin/silymarin and PCA cells have
shown the pleiotropic anticancer effects leading to cell growth inhibition in
culture and nude mice. The underlying mechanisms of silibinin/silymarin
efficacy against PCA involve alteration in cell cycle progression, and
inhibition of mitogenic and cell survival signaling, such as epidermal growth
factor receptor, insulin-like growth factor receptor type I and nuclear factor
kappa B signaling. Silibinin also synergizes the therapeutic effects of
doxorubicin in PCA cells, making it a strong candidate for combination
chemotherapy. Silibinin/ silymarin also inhibits the secretion of proangiogenic
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factors from tumor cells, and causes growth inhibition and apoptotic death of
endothelial cells accompanied by disruption of capillary tube formation on
Matrigel. More importantly, silibinin inhibits the growth of  in vivo  advanced
human prostate tumor xenograft in nude mice.”
 Leyon Varghese et al., 2005 reported about the “Silibinin Efficacy against
Human Hepatocellular Carcinoma”
“The author reported that Silibinin strongly inhibited growth of both HepG2
and Hep3B cells with a relatively stronger cytotoxicity in Hep3B cells, which
was associated with apoptosis induction. Silibinin also caused G1 arrest in
HepG2 and both G1 and G2-M arrests in Hep3B cells. Mechanistic studies
revealed that silibinin induces Kip1/p27 but decreases cyclin D1, cyclin D3,
cyclin E, cyclin-dependent kinase (CDK)-2, and CDK4 levels in both cell
lines. In Hep3B cells, silibinin also reduced the proteinlevels of G2-
Mregulators. Furthermore, silibinin strongly inhibited CDK2, CDK4, and
CDC2 kinase activity in these HCC cells. Conclusion: Together, these results
for the first time identify the biological efficacy of silibinin against HCC cells,
suggesting the importance of conducting further investigations in preclinical
HCC models, especially on in vivo efficacy, to support the clinical usefulness
of silibinin against hepatocellular carcinoma in addition to its known clinical
efficacy as an antihepatotoxic agent.”
 Noël J.-M. Raynal et al., 2007 reported about the “Antileukemic Activity of
Genistein, a Major Isoﬂavone Present in Soy Products”
“ The author reported the in vitro and in vivo antileukemic activity of
genistein , a major isoﬂavone present in soy. Observed that it produced a dose-
and time-dependent  antineoplastic activity against myeloid and lymphoid
leukemic cell lines. In addition, genistein treatment of the leukemic cells
reactivated tumor suppressor genes that were silenced by aberrant DNA
methylation. A genistein-enriched diet produced a moderate, but signiﬁcant,
antileukemic effect in mice. The limited extent of this in vivo response may
have been due to the rapid metabolic inactivation of genistein in mice. Due to
the longer half-life of genistein in humans, a soy-enriched diet has the potential
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to produce plasma levels of this isoﬂavone in the range of the concentrations
used in vitro that produced an antileukemic activity.”.
 Rana P. Singh et al., 2001 reported about the “Detrimental effect of cancer
preventive phytochemicals silymarin, genistein and epigallocatechin 3-gallate
on epigenetic events in human prostate carcinoma DU145 cells.”
“The author reported that Treatment of cells with silymarin, genistein or
EGCG at 100–200 μM resulted in a complete inhibition of TGFα-caused
activation of erbB1 followed by a moderate to strong inhibition (10–90%) of
Shc activation without an alteration in their protein levels. Silymarin and
genistein, but not EGCG, also inhibited (10% to complete) ERK1/2 activation
suggesting that these agents impair erbB1-Shc-ERK1/2 signaling in DU145
cells. In other studies, silymarin, genistein or EGCG caused a strong induction
of Cip1/p21 (up to 2.4-fold) and Kip1/p27 (up to 150-fold), and a strong
decrease in CDK4 (40–90%) but had moderate effect on CDK2, and cyclins
D1 and E. An enhanced level of CDKIs also led to an increase in their binding
to CDK4 and CDK2. Treatment of cells with silymarin, genistein or EGCG
also resulted in 50–80% cell growth inhibition at lower doses, and complete
inhibition at higher doses. In contrast to silymarin, higher doses of genistein
showed cytotoxic effect causing 30–40% cell death. A more profound
cytotoxic effect was observed with EGCG accounting for 50% cell death at
lower doses and complete loss of viability at higher doses.”
 Ian R. Record et al., 1995 reported about the “The antioxidant activity of
genistein in vitro. “
“The author reported that genestein  proved to be effective against UVA and
UVB or peroxyl radical-induced lipid peroxidation in liposomes. Genistein
was however ineffective in preventing conjugated diene formation in linoleic
acid micelles. Other peroxidative systems involving hydrogen peroxide, such
as metmyoglobin peroxidase activity and Fel ascorbate/hydrogen peroxide
oxidation of liposomes, were inhibited by genistein. As measured by catechol
decolorization, genistein did not appear to chelate iron. Genistein removed
hydrogen peroxide efficiently when phenol red was coupled with peroxidase;
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however, when o-dianisidine was used as the color reagent there was no
apparent loss of hydrogen peroxide, possible due to oxidation of the dye by the
product of genistein and hydrogen peroxide. This study provides further
evidence that genistein is an effective scavenger of hydrogen peroxide but is
less effective against other peroxidative systems.”
 Aslamuzzaman kazi et al., 2003 reported about the “Inhibition of the
proteasome activity, a novel mechanism associated with the tumor cell
apoptosis-inducing ability of genistein.”
“The author reported that genistein inhibits the proteasomal chymotrypsin
like activity in vitro and in vivo. Computational docking studies suggest that
the interaction of genistein with the proteasomal β5 subunit is responsible for
inhibition of the chymotrypsin-like activity. Inhibition of the proteasome by
genistein in prostate cancer LNCaP and breast cancer MCF-7 cells is
associated with accumulation of ubiquitinated proteins and three known
proteasome target proteins, the cyclin-dependent kinase inhibitor p27Kip1,
inhibitor of nuclear factor-κB (IκB-α), and the pro-apoptotic protein Bax.
Genistein-mediated proteasome inhibition was accompanied by induction of
apoptosis in these solid tumor cells. Finally, genistein induced proteasome
inhibition and apoptosis selectively in simian virus 40-transformed human
fibroblasts, but not in their parental normal counterpart. Our results suggest
that the proteasome is a potential target of genistein in human tumor cells and
that inhibition of the proteasome activity by genistein might contribute to its
cancer-preventive properties.”
 M.A. Louis Jeune et al., 2005 reported about the “Anticancer Activty of
promigranets extracts and genistein on human breast cancer cell lines.”
“The author reported that pomegranate extracts and genistein had significant
(dose- and time-dependent) cytotoxic and growth inhibition effects on MCF-7
cancer cells. Both growth inhibition and cytotoxicity were significantly higher
(P < .01) in the combination treatments than in the single treatments with
either agent. The data revealed that both drugs in single and in combination
treatments induced apoptosis in MCF-7 cells. Apoptotic induction in the
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combination treatments was significantly higher (P < .01) than in single
treatments. Both pomegranate extracts and genistein inhibit the growth of
MCF-7 breast cancer cells through induction of apoptosis, with combination
treatment being more efficacious than single treatments.”
 Li, Yiwei MD et al., 2004 reported about “Apoptosis-Inducing Effect of
Chemotherapeutic Agents Is Potentiated by Soy Isoflavone Genistein, a
Natural Inhibitor of NF-[kappa]B in BxPC-3 Pancreatic Cancer Cell Line.”
“The author reported that Genistein has been shown to inhibit the growth of
various cancer cells in vitro and in vivo without toxicity to normal cells. The
antitumor effects of genistein could be in part due to inactivation of NF-κB
activity. In contrast, chemotherapeutic agents inadvertently induce NF-κB
activity, which may lead to chemoresistance. In this study, we investigated
whether the inactivation of NF-κB by genistein would enhance the efficacy of
chemotherapeutic agents. The combination of 30 μmol/L genistein with 1
nmol/L docetaxel or 100 nmol/L cisplatin elicited significantly greater
inhibition of cell growth compared with either agent alone. The combination
treatment induced more apoptosis in BxPC-3 cells compared with single
agents. Moreover, the NF-κB activity was significantly increased within 2
hours of docetaxel or cisplatin treatment, and the NF-κB-inducing activity of
these agents was completely abrogated in cells pretreated with genistein. These
results clearly suggest that genistein pretreatment, which inactivates NF-κB
activity, together with other cellular effects of genistein, may contribute to
increased cell growth inhibition and apoptosis inducing effects of nontoxic
doses of docetaxel and cisplatin, which could be a novel strategy for the
treatment of pancreatic cancer.”
 Fatih M. Uckun et al., 1998 reported about the “In Vivo Toxicity,
Pharmacokinetics, and Anticancer Activityof Genistein Linked to
Recombinant Human Epidermal Growth Factor”
“The author reported that Epidermal growth factor receptor (EGFR)-
associated protein tyrosine kinase (PTK) complexes have vital anti- apoptotic
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functions in human breast cancer cells. We have shown previously that
targeting the naturally occurring PTK inhibitor genistein to the EGFR-
associated PTK corn- plexes using the EGF-Genistein (Gen) conjugate triggers
rapid apoptotic cell death in human breast cancer cells and abrogates their in
vitro clonogenic growth. In the present study, we examined the in vivo toxicity
profile, pharmaco- Idnetics, and anticancer activity of EGF-Gen. No toxicities
were observed in mice treated with EGF-Gen at dose levels as high as 40
mgfkg administered i.p. as a single dose or 140 mg/kg administered i.p. over
28 consecutive days. EGF-Gen significantly improved tumor-free survival in a
severe combined immune deficiency (SCm) mouse xenograft model of human
breast cancer”
 Anil K. Tyagi et al., 2002 reported about the “ Silibinin Strongly Synergizes
Human Prostate Carcinoma DU145 Cells to Doxorubicin-induced Growth
Inhibition, G2-M Arrest, and Apoptosis”
“The author reported that Silibinin strongly synergized the growth-inhibitory
effect of doxorubicin in prostate carcinoma DU145 cells ,which was associated
with a strong G2-M arrest in cell cycle progression, showing 88%cells in G2-
Mphase by this combination compared with 19 and 41% of cells in silibinin
and doxorubicin treatment alone, respectively. The underlying mechanism of
G2-M arrest showed a strong inhibitory effect of combination on cdc25C,
cdc2/p34, and cyclin B1 protein expression and cdc2/p34 kinase activity. More
importantly, this combination caused 41%apoptotic cell death compared with
15%by either agent alone. Silibinin and doxorubicin alone as well as in
combination were also effective in inhibiting the growth of androgen-
dependent prostate carcinoma LNCaP cells.”
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AIM AND OBJECTIVE
The major aim of this study is to evaluate the antitumor activity of the two
flavonoids 1.Silibinin 2.genestein in combined on breast cancer cell lines and colon
cancer cell lines. The silibinin and genestein has shown the antitumor activity on
prostate cancer in combined.
Silibinin and Genestein has shown the cell growth inhibition in culture by
alteration of cell cycle progression and inhibition of mitogenic and cell survival
signaling. Both the compounds have shown the proangiogenic factor from tumor
cell.
Cancer is one of the dangerous, lethal and a major challenging disease to
medicinal system to produce more potent and the site specific anti-cancer drugs.
Vast number investigations are going on to find out the potent and safer new anti-
cancer drugs.
Flavanoids have a capacity to elevate the antioxidant levels and prevent the
free radical reactions and also reported that flavanoids have an antitumor activity.
Flavanoids are also called as free radical scavengers because of their activity on the
free radicals and ROS. Hence in the present study silibinin and genestein which are
novel  flavanoids was used for evaluating the antitumor activity due to its free
radical scavenging activity since many studies done previously on flavanoid
antioxidant and antitumour activities.
Till there is no study on the combined effect of the silibinin and genestein on
the breast cancer and colon cancer. Thus the study was chosen to find out the
antitumor activity and antioxidant activity of the two flavonoids in combined and to
compare it with the actions of both compound in single.
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PLAN OF WORK FOR THE STUDY
1. Collecting the compounds.
2. Invitro cytotoxicity studies.
a. Tetrazolium salt assay
3. Invitro cytoprotectivity studies.
a. Estimation of lipid peroxidation.
b. Estimation of reduced glutathione.
c. Estimation of LDH leakage.
4. Results of cytotoxic and cytoprotective activity.
5. Interpretation of the results.
6. Discussion.
7. Conclusion.
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COMPOUND PROFILE
GENISTEIN
Genistein
IUPAC name
5,7-Dihydroxy-3-(4-hydroxyphenyl)chromen-4-one
Other names
4',5,7-Trihydroxyisoflavone
Properties
Molecular formula C15H10O5
Molar mass 270.24 g mol−1
Exact mass 270.052823
Meltimg point/freezing point > 280 °C
STORAGE
Provide appropriate exhaust ventilation at places where dust is
formed.
Protect against light. Store in cool place. Keep container tightly
closed in a dry and well-ventilated place
.Recommended storage temperature: -20 °C
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Genistein is a phytoestrogen (estrogen-like chemical compound present in
plants) that is derived from certain plant precursors by human metabolism. They are
naturally occurring chemical constituents that may interact with estrogen receptors
to produce weak estrogenic or anti-estrogenic effects.  They are composed of a wide
group of nonsteroidal compounds similar in structure and function to human
estrogens . A conspicuous feature of the chemical structure of phytoestrogens is the
presence of a phenolic ring that, with few exceptions, is a prerequisite for binding to
the estrogen receptor. For this reason, phytoestrogens can act as weak estrogen
agonists, partial agonists,  or as antagonists to endogenous estrogens (such  as
estradiol) and xenoestrogens (including phytoestrogens) with estrogen receptors in
both animals and humans. Therefore, working as estrogen mimics, phytoestrogens
may either have the same effects as estrogen or block estrogen’s effects. There are
three major classes of plant chemical compounds that have estrogen-like actions in
the body.  They are lignans (enterolactone, enterodiol), isoflavones (genistein,
daidzein, biochanin A), and coumestans. The two major chemical classes of
phytoestrogens found in people’s diets are lignans (enterodiol and enterolactone)
and isoflavones (daidzein, genistein, and glycitein). Lignans are the main class of
phytoestrogens present in Western diets.  Genistein is an isoflavone.
BIOLOGICAL EFFECT
Molecular function
Genistein influences multiple biochemical functions in living cells:
 activation of PPARs
 inhibition of several tyrosine kinases
 inhibition of topoisomerase
 direct antioxidation with some proxidative features
 activation of Nrf2 antioxidative response
 stimulation of autophagy
 activation of estrogen receptor beta
 inhibition of the mammalian hexose transporter GLUT1
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 contraction of several types of smooth muscles
 modulation of CFTR channel, potentiating its opening at low concentration and
inhibiting it a higher doses.
Activation of PPARs
Isoflavones genistein and daidzein bind to and transactivate all three
Parxisomal-proliferator activated receptors (PPAR) isoforms, α, δ, and γ. For
example, membrane-bound PPARγ-binding assay showed that genistein can directly
interact with the PPARγ ligand binding domain and has a measurable Ki of 5.7 mM.
Gene reporter assays showed that genistein at concentrations between 1 and 100 uM
activated PPARs in a dose dependent way in KS483 mesenchymal progenitor cells,
breast cancer MCF-7 cells, T47D cells and MDA-MD-231 cells, murine
macrophage-like RAW 264.7 cells, endothelial cells and in Hela cells. Several
studies have shown that both ERs and PPARs influenced each other and therefore
induce differential effects in a dose-dependent way. The final biological effects of
genistein are determined by the balance among these pleiotrophic actions.
Tyrosine kinase inhibitor
The main known activity of genistein is tyrosine kinase inhibitor, mostly
of epidermal growth factor receptor (EGFR). Tyrosine kinases are less widespread
than their ser/thr counterparts but implicated in almost all cell growth and
proliferation signal cascades.
Redox-active - not only antioxidant
Genistein may act as direct antioxidant, similar to many other isoflavones,
may alleviate damaging effects of free radicals in tissues.
The same molecule of genistein, similar to many other isoflavones, by generation of
free radicals poison topoisomerase II, enzyme important for maintaining DNA
stability.
Human cells turn on beneficial, detoxyfying Nrf2 factor in response to
genistein insult. This pathway may be responsible for observed health maintaining
properities of small doses of genistein. (Krzysztof Polkowski et. al, 2000)
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Anthelmintic
The root-tuber peel extract of the leguminous plant Felmingia vestita is the
traditional anthelmitic of the Khasi tribes of India. While investigating its
anthelmintic activity, genistein was found to be the major isoflavone responsible for
the deworming property. Genistein was subsequently demonstrated to be highly
effective against intestinal parasites such as thepoultry cestode Raillietina
echinobothrida, the pork trematode Fasciolopsis buski, and the sheep liver
fluke Fasciola hepatica. It exerts its anthelmintic activity by inhibiting the enzymes
of glycolysis and glycogenolysis, and disturbing the Ca2+
homeostasis and NO activity in the parasites. It has also been investigated in human
tapeworms such asEchinococcus multilocularis and E. granulosus metacestodes that
genistein and its derivatives, Rm6423 and Rm6426, are potent cestocides.
Atherosclerosis
Genistein protects against pro-inflammatory factor-induced vascular
endothelial barrier dysfunction and inhibits leukocyte-endothelium interaction,
thereby modulating vascular inflammation, a major event in
the pathogenesis of atherosclerosis.
Cancer links
Genistein and other isoflavones have been identified as angiogenesis
inhibitors, and found to inhibit the uncontrolled cell growth of cancer, most likely by
inhibiting the activity of substances in the body that regulate cell division and cell
survival (growth factors). Various studies have found that moderate doses of
genistein have inhibitory effects on cancers of theprostate,
cervix, brain, breast and colon. It has also been shown that genistein makes some
cells more sensitive to radio-therapy.; although, timing of phytoestrogen use is also
important
Genistein's chief method of activity is as a tyrosine kinase inhibitor. Tyrosine
kinases are less widespread than their ser/thr counterparts but implicated in almost
all cell growth and proliferation signal cascades. Inhibition of DNA topoisomerase
II also plays an important role in the cytotoxic activity of genistein. Genistein has
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been used to selectively target pre B-cells via conjugation with an anti-CD19
antibody.
Studies on rodents have found genistein to be useful in the treatment
of leukemia, and that it can be used in combination with certain other antileukemic
drugs to improve their efficacy.
Estrogen receptor - more cancer links
Due to its structure similarity to 17β-estradiol (estrogen), genistein can
compete with it and bind to estrogen receptors. However, genistein shows much
higher affinity toward estrogen receptor β than toward estrogen receptor α.
Data from in vitro and in vivo research confirms that genistein can increase rate of
growth of some ER expressing breast cancers. Genistein was found to increase the
rate of proliferation of estrogen-dependent breast cancer when not cotreated with an
estrogen antagonist. It was also found to decrease efficiency
of tamoxifen and letrozole - drugs commonly used in breast cancer
therapy. Genistein was found to inhibit immune response towards cancer cells
allowing their survival.
Effects in males
Isoflavones can act like estrogen, stimulating development and maintenance
of female characteristics, or they can block cells from using cousins of estrogen. In
vitro studies have shown genistein to induce apoptosis of testicular cells at certain
levels, thus raising concerns about effects it could have on male fertility; however, a
recent study found that isoflavones had "no observable effect on endocrine
measurements, testicular volume or semen parameters over the study period." in
healthy males given isoflavone supplements daily over a 2 month period. (Richard
A. Dixon, 2004)
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COMPOUND PROFILE
SILIBININ
Silibinin
IUPAC
(2R,3R)-3,5,7-trihydroxy-
2-[(2R,3R)-3-(4-hydroxy-3-methoxyphenyl)-2-(hydroxymethyl)
-2,3-dihydrobenzo[b][1,4]dioxin-6-yl]chroman-4-one
Properties
Molecular formula C25H22O10
Molar mass 482.44 g mol−1
STORAGE
Store in cool place.
Keep container tightly closed in a dry and well-ventilated place.
Recommended storage temperature: -20 °C.
Avoid contact with skin and eyes.
Avoid formation of dust and aerosols.
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Silibinin , also known as silybin, is the major active constituent of silymarin,
standardized extract of the milk thistle seeds, containing mixture of flavonolignans
consisting of among others of silibinin, isosilibinin, silicristin and silidianin.
Silibinin itself is mixture of two diastereomers Silibinin A and Silybinin B in
approximately equimolar ratio. Both in vitro and animal research suggest that
silibinin has hepatoprotective (antihepatotoxic) properties that protect liver cells
against toxins. Silibinin has also demonstrated anti-cancer effects against human
prostate adenocarcinoma cells, estrogen-dependent and -independent human breast
carcinoma cells, human ectocervical carcinoma cells, human colon cancer cells, and
both small and nonsmall human lung carcinoma cells.
PHARMACOLOGY
Poor water solubility and bioavailability of silymarin led to the development
of enhanced formulations. Silipide (trade name Siliphos), a complex of silymarin
and phosphatidylcholine (lecithin), is about ten times more bioavailable than
silymarin. It has been also reported that silymarin inclusion complex with β-
cyclodextrin is much more soluble than silymarin itself. There have also been
prepared glycosides of silybin, which show better water solubility and even stronger
hepatoprotective effect.
Silymarin, as other flavonoids, has been shown to inhibit P-glycoprotein-
mediated cellular efflux. The modulation of P-glycoprotein activity may result in
altered absorption and bioavailability of drugs that are P-glycoprotein substrates. It
has been reported that silymarin inhibits cytochrome P450 enzymes and an
interaction with drugs primarily cleared by P450s cannot be excluded.
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BIOLOGICAL   EFFECTS
LIVER
Milk thistle prevents toxins from entering the liver by guarding the organ's
numerous doorways-the membranes of liver cells. By slowing the rate at which the
liver absorbs harmful substances, the toxins are excreted through the kidneys before
they can cause liver damage. Much of Milk Thistle's protective effect is due to the
flavonoid complex silymarin, which acts as a powerful antioxidant, combining with
and thus neutralizing harmful free radicals that result from normal metabolic
processes and from the breakdown of toxic substances. At least 10 times as potent as
vitamin E, silymarin also helps increase levels of two additional antioxidants,
glutathione and superoxide dismutase (SOD). A laboratory study showed that
silymarin may increase glutathione content in the liver and intestines by up to 50
percent. Silymarin also increases the activity of SOD in erythrocytes (red blood
cells) and lymphocytes (white blood cells) formed in the lymphatic tissue in patients
with liver disease.Because silymarin is a potent antioxidant in the stomach and
intestines, it may also have a role to play in treating inflammatory conditions such as
colitis and ulcers.
CANCER
An antioxidant like silymarin would have anti-cancer effects, the molecular
effects of silymarin that give it powerful anti-cancer properties have amazed even
the scientific community. In the last few years, researchers have begun to discover
exactly why silymarin has such broad anti-cancer properties.Among the most
promising cancer fighting strategies that researchers are trying to develop are
angiogenesis inhibitors (which stop the proliferation of blood vessels that feed
tumors), cell cycle regulators, and selective promoters of cancer cell death.
Amazingly, silymarin has been shown to possess all of these abilities. A review of
research into silymarin's effects on prostate cancer concluded that silymarin has a
huge potential to interfere with many molecular events involved in cancer cell
growth, progression, and angiogenesis. One study done in August 2008 indicated
that silymarin may inhibit metastasis in prostate cancer. Another study done in
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September 2008 identified the strong efficacy of silymarin in prostate cancer
prevention and intervention, as reported in previous studies.Because of this you
would expect silymarin to have activity against a broad range of cancer types, and an
examination of the literature shows that silymarin has impressive effects against
prostate, colon, ovarian, skin, lung, breast, and cervical cancers in preliminary
studies. In the cases of prostate and ovarian cancer, human clinical trials are
currently underway both in the USA and Europe.
(www.Naturalhealthconsults.com)
TOXICITY
The acute toxicity of silymarin and silybin were investigated by oral and
intravenous route in various animal species. No mortality or any signs of adverse
effects were observed after silymarin at oral doses of 20 g/kg in mice and 1 g/kg in
dogs. The median lethal dose (LD50) after intravenous infusion values are 400 mg/kg
in mice, 385 mg/kg in rats and 140 mg/kg in rabbits and dogs. These data
demonstrate that the acute toxicity of silymarin is very low.
Similarly, its subacute and chronic toxicity are very low; the compound is
also devoid of embryotoxic potential. (http://www.wisegeek.com/what-are-the-
medical-uses-of-silibinin.htm)
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MATERIALS AND METHODS
Silibinin and Genistein was purchased from Sigma Aldrich and constituted in
dimethyl sulfoxide (DMSO) solvent as 0,100,150 and 200 mg/mL solutions
(containing 0.1% DMSO) and frozen at -37°C until used. Culture media, RPMI 1640,
fetal calf serum, antibiotics, trypsin-EDTA, and other reagents were purchased from
Sigma Chemical Co. (St. Louis, MO). Breast cancer cells (MCF-7), Human Colon
cancer cell line, were obtained from the National center for cell Sciences, Pune (MS)
and MCF-10A normal breast cell line, human colon tissue from MGM medical
college, Aurangabad. Cells were grown and maintained as monolayers in 25-mm2
tissue culture flasks (Sigma) in RPMI 1640 growth medium, containing 15 mM
HEPES, and supplemented with 0.45% (wt/wt) gluose, 5.0% fetal calf serum, and 100
U/mL penicillin plus 100 ug/mL streptomycin.
Cell culture
To assess the cytotoxicity on breast cancer cells and colonl cancer cell line to
single and combination treatments with silibinin and genistein, cells were subcultured
under 5% CO2 at 37°C for 48 hours to reach 80% confluence.
The cells were harvested by gentle scraping with a cell scraper and
resuspended in the medium. From the suspension, 2.5 X 10-4 cells in 200 uL was
dispensed into each well of 24-well microtiter plates (MTPs) and cultured under the
same conditions described above for 48 hours to allow adherence of the cells.
The supernatants were gently aspirated, and genistein and/or silibinin were
added over a range of three cytotoxic concentrations  in single and combination
treatments. In preliminary studies the 50% inhibitory concentration (IC50) of silibinin
20 ug, and that for genistein was 20 ug. Therefore in the combination treatments, the
IC50 of one agent was used against varying concentrations of the other. All treated
MTPs were incubated at 37°C in a humidified atmosphere of 5% CO2 in air for a
maximum of 72hours.
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At each time point, the media were replenished with equal volumes of the
appropriate reagent concentration. At 72 hours of incubation, the cells in each MTP
well were processed for the 3-(4,5-dimethylthiazol-2- yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H- tetrazolium, inner salt (MTT) assay.
To assess the cytoprotectivity on breast cell line and colonl cell line to single
and combination treatments with silibinin and genistein, cells were subcultured under
5% CO2 at 37°C for 48 hours to reach 80% confluence.
The cells were harvested by gentle scraping with a cell scraper and
resuspended in the medium. From the suspension, 2.5 X 10-4 cells in 200 uL was
dispensed into each well of 24-well microtiter plates (MTPs) and cultured under the
same conditions described above for 48 hours to allow adherence of the cells.
The supernatants were gently aspirated, and genistein and/or silibinin were
added over a range of three cytotoxic concentrations in single and combination
treatments. In preliminary studies the 50% inhibitory concentration (IC50) of silibinin
20 ug, and that for genistein was 20 ug. Therefore in the combination treatments, the
IC50 of one agent was used against varying concentrations of the other. All treated
MTPs were incubated at 37°C in a humidified atmosphere of 5% CO2 in air for a
maximum of 72hours. After that the culture medium was removed. Then the cells
were treated with H2O2 (6.5 mmol/L, 1.5 h). The cells in control group, containing
equal volume of DMSO but without any addition of tested compounds, and were not
oxidative injured. The cells in model group, containing equal volume of DMSO,
without any addition of tested compounds, but were oxidative injured. Then, all
groups were processed immediately for biochemical assays. (ZHAO Xin-huai,2009)
At24and72 hours of incubation, 100 uL of the supernatant from each well was
gently aspirated into micro centrifuge tubes and stored at -37°C until assayed for
lactate dehydrogenase (LDH) enzyme activity.
Chapter 6 Materials And Methods
Dept. of Pharmacology 60 JKK Nattraja College of Pharmacy
MTT assay
MTT is a yellow water soluble tetrazolium salt. A mitochondrial enzyme in
living cells, succinate-dehydrogenase, cleaves the tetrazolium ring, converting the
MTT to an insoluble purple formazan. Therefore the amount of formazan produced is
directly proportional to the number of viable cells.
After 72h of incubation, 15 ul of MTT (5 mg/ml) in phosphate buffered saline
(PBS) was added to each well and incubated at 370c for 4h. the medium with MTT
was flicked off and the formed formazan crystals were solubilized in 100 ul of DMSO
and then measured the absorbacne at 570 nm using micro plate reader. (Kinzler et. al.
2007)
LDH assay
LDH activity was measured by a non-radioactive protocol using the LDH
cytotox kit. The LDH assay is based on the release of the cytosolic enzyme, LDH,
from cells with damaged cellular membranes. Thus, in cell culture, the course of drug-
induced cytotoxicity can be followed quantitatively by measuring the activity of LDH
in the supernatant.
The previously frozen supernatant was thawed for LDH determination.
Briefly, 100 uL per well of each cell-free supernatant was transferred in triplicates
into wells in a 96-well MTP, and 100 uL of LDH-assay reaction mixture (dye-catalyst
mixture from the kit) was added to each well. After a 3-hour incubation under
standard conditions, the absorbance/optical density of the color generated was read on
a Multi scan biochromatic automatic microplate reader at 490 nm.
MDA assay
The formation of MDA in cells was measured by the thiobarbituric acid
(TBA) method[8]. Briefly, a 0.5 ml aliquot of the cell suspension was added to 0.5 ml
of reaction medium containing TBA (0.375%, m/V) and TCA (15%, m/V) in 0.25
mol/L HCl. The mixture was heated in boiling water for 15 min, cooled to room
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temperature, and centrifuged to remove insoluble materials. Then the mixture was
measured at 532 nm using 1,1,3,3-tetraethoxypropane as standard and MDA content
was expressed as mmol/L MDA/g protein. Protein content was determined by Lowry's
method using bovine serum albumin as standard.
GSH assay
Both Cell Lines were washed and harvested in 0.5 ml of PBS with 0.1% Triton
X-100. After 10 min of incubation, the mixture was centrifuged (3000×g, 10 min,
4°C) and 0.3 ml of the supernatant was mixed with 1.0 ml Tris-base (0.8 mol/ L)-
EDTA (0.02 mol/L) buffer, pH 8.9. Following the addition of 0.1 ml of DTNB (0.01
mol/L) in methanol[7]. The content of reduced GSH in cells was measured at 412 nm
and expressed as mg GSH/g protein. Protein content was also determined by Lowry's
method. (ZHAO Xin-huai,2009)
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RESULTS
Silibinin and Genistein cytotoxicity on Breast Cancer cell line
Sr
No
Drugs Cytotoxicity at three concentrations (%)
100 ug/ml 150ug/ml 200ug/ml
1 Control 0% 0% 0%
2 Silibinin 79.375% 84.565% 91.10%
3 Genistein 61.20% 67.66% 74.55%
4 Silibinin + Genistein 83% 86.11% 91.10%
Note : Cytotoxicity in control group was 0. Value were expressed as means of
triplicate ± standard deviation
Graph:- Silibinin and Genistein cytotoxicity on Breast Cancer cell line
On Breast cancer cell lines, increase in concentration of the compounds has
shown the prominent activity. With the Increase in concentration follows marked
inhibition of the growth of cancerous cells. Whereas the combination of the two
compounds has shown the very significant activity on the breast cancer cell lines.
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Viability of Breast cancer cells in the presence of Silibinin and
Genistein.
Sr
No
Drugs Cell viability at three concentrations (%)
100 ug/ml 150ug/ml 200ug/ml
1 Control 100% 100% 100%
2 Silibinin 20.625% 15.435% 8.90%
3 Genistein 38.80% 32.34% 25.45%
4 Silibinin + Genistein 17% 13.89% 8.90%
Note : Cell viability in control group was 100. Value were expressed as means of
triplicate ± standard deviation
Graph:- Vaibility of breast cells in the persence of silibinin and genistein.
Viability of the breast cancer cells is the (100 – cytotoxicity). In this case as the
cytotoxicity goes on increasing  the viability of the cells goes on decreasing.
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Silibinin  and Genistein cytotoxicity on Colon Cancer Cell Lines.
Sr
No
Drugs Cytotoxicity at three concentrations (%)
100 ug/ml 150ug/ml 200ug/ml
1 Control 0% 0% 0%
2 Silibinin 64.11% 72.33% 88.11%
3 Genistein 60.54% 70.66% 82.55%
4 Silibinin + Genistein 74.65% 78.74% 90.55%
Note : Cytotoxicity in control group was 0. Value were expressed as means of
triplicate ± standard deviation
Graph:- Silibinin  and Genistein cytotoxicity on Colon Cancer Cell Lines.
On Colon cancer cell lines, both silibinin and genestien hs shown the
inhibitory effect. Whereas the combination of the silibinin and genestein has found
to be more effective to prevent the growth of the cancerous cell lines. When we are
increasing the concentration the activity has also increased in the dose dependent
manner.
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Viability of Colon cancer cells in the presence of Silibinin and
Genistein.
Sr
No
Drugs Cell viability at three concentrations (%)
100 ug/ml 150ug/ml 200ug/ml
1 Control 100% 100% 100%
2 Silibinin 35.89 27.67 11.89%
3 Genistein 39.46% 29.34% 17.45%
4 Silibinin + Genistein 25.35% 21.26% 9.45%
Note : Cell viability in control group was 100. Value were expressed as means of
triplicate ± standard deviation
Graph:- Vaibility of colon cells in the persence of silibinin and genistein.
Viability of the breast cancer cells is the (100 – cytotoxicity). In this case as the
cytotoxicity goes on increasing  the viability of the cells goes on decreasing.
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Cytoprotective  effect of silibinin and Genisteinon Breast cell line.
Sr.
No.
Concentration
Ug/ml
Viability
(%)
LDH MDA
mmol/g
GSH
mg/g
1 Control 100 -- 0.7 ± 0.2 27.98 ± 0.9
2 H2O2 4.3 ± 0.1 2.2 ± 0.2 11.2 ± 0.4
3 Silibinin
100 20.625 4.0 ± 0.2ns 1.8 ± 0.2ns 10.8 ± 0.6ns
150 15.435 3.1 ± 0.3** 1.3 ± 0.4* 9.3 ± 0.5**
200 8.90 2.8 ± 0.5** 1.2 ± 0.2** 12.7 ± 0.3**
4 Genistein
100 38.80 3.6 ± 0.2ns 1.6 ± 0.3* 8.9 ± 0.5**
150 32.34 2.6 ± 0.5** 1.2 ± 0.2** 10.3 ± 0.3ns
200 25.45 2.8 ± 0.5** 1.2 ± 0.2** 13.1 ± 0.7**
5 Silibinin
+Genistein
100 17 3.0 ± 0.4** 1.1 ± 0.3** 10.0 ± 0.4**
150 13.89 2.7 ± 0.4** 0.9 ± 0.2** 11.2 ± 0.4ns
200 8.90 2.6 ± 0.4** 1.1 ± 0.5** 12.5 ± 0.4**
Note : Cell viability in control group was 100. Value were expressed as means of
triplicate ± standard deviation . The different  upper stars represents the significant
differences comparing to model group; *(p< 0.05), ** (p < 0.01), ***(p<0.001).
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Cytoprotective effect of silibinin and Genistein on Colon  Cell Lines.
Sr.
No.
Concentration
Ug/ml
Viability
(%)
LDH MDA
mmol/g
GSH
mg/g
1 Control 100 -- 0.7 ± 0.2 27.98 ± 0.9
2 H2O2 2.3 ± 0.1 1.7 ± 0.1 13.6 ± 0.8
3 Silibinin
100 35.89 2.3 ± 0.2ns 1.9 ± 0.2ns 9.7 ± 0.4***
150 27.67 1.4 ± 0.2** 1.1 ± 0.1** 11.3 ± 0.9**
200 11.89 1.4 ± 0.2** 1.1 ± 0.1** 13.7 ± 0.3ns
4 Genistein
100 39.46 1.9 ± 0.2ns 1.4 ± 0.2ns 11.8 ± 0.6**
150 29.34 1.3 ± 0.3** 1.1 ± 0.1** 10.7 ± 0.2***
200 17.45 1.2 ± 0.2** 1.0 ± 0.1*** 12.1 ± 0.3**
5 Silibinin
+Genistein
100 25.35 1.4 ± 0.3** 1.3 ± 0.2ns 8.8 ± 0.7***
150 21.26 1.3 ± 0.1** 1.1 ± 0.1** 10.5 ± 1.0**
200 9.4 1.0 ± 0.2*** 1.0 ± 0.2** 10.9 ± 0.3**
Note : Cell viability in control group was 100. Value were expressed as means of
triplicate ± standard deviation. The different  upper stars represents the significant
differences comparing to model group; *(p< 0.05), ** (p < 0.01), ***(p<0.001).
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Statistical analysis
Data were expressed as mean ±standard deviation (SD)of at least three independent
assays and subjected to a one- way analysis of variance (ANOVA) using SAS
version 9.3 software. P values≤0.05 were considered as statistically significant.
Toxicity level was calculated by the following formula:
Cytotoxicity% = 1− Mean absorbance of toxicant ×100 Mean absorbance of
negative control
Viability % = 100 - Cytotoxicity %
To diminish test error level, MTT strain was added to some wells without cells and
along with other wells, absorbance level was read and ultimately subtracted from
whole the absorbance.
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DISCUSSION
Silibinin and genistein inhibit growth and proliferation of breast cancer cells
and colon cancer cells.
The Silibinin and genistein on inhibition of growth and proliferation of
breast cancer cells (BCC) and Colon cancer cells (CCC) were determined by using
MTT bioassays. In single and combination treatments, both silibinin and genistein
inhibited cell growth and decreased cell survival through induction of cell death in
both a time and dose dependent manner. The data obtained revealed that BCC were
more sensitive to the combination treatment than to the single treatments (P < .01).
For comparative studies, normal (non-cancerous) cells were subjected to
identical treatments and bioassay analysis. The results obtained demonstrated the
BCC and CCC to exhibit significantly cytotoxicity in response to both silibinin and
genistein when compared with the normal cells. In addition to its cytotoxic effect the
silibinin and genistein has shown the cytoprotective effect on the normal cell lines.
This indicates that the compounds protects the normal host cells and killing the
cancerous cells.
The results indicate that both silibinin and genistein have significant
inhibitory effect on the growth rate of BCC and CCC. The result also demonstrate
that both silibinin and genistein, in single and combination treatments, induced
apoptosis in the cancer cells in a time and dose-dependent manner. Growth
inhibition effects of both silibinin and genistein have been observed in many human
adenocarcinoma cell lines.
The growth inhibition correlated significantly with the degree of treatment
induced cell death and induction of apoptosis in the targeted cells. The significant
correlation between the two non-radioactive assays (LDH and MDA) justifies the
authenticity of the results.
Treatment of BCC  with silibinin or genistein result in significant increase in
cell death(p<0.01), indicating a significant cell injury this is same with colon cancer
cell line. But when combination is there it is very much significantly work on both.
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CONCLUSION
The present investigation was carried out to evaluate the in-vitro cytotoxic
and cytoprotective activity of silibinin and genistein on breast and colon cell lines.
It was found that there was significant decrease in the viability of the cells,
when the cells are treated with the two compounds silibinin and genistein. The
compounds has shown marked cytotoxicity in single and in combination treatments.
The compounds has shown a significant results in combination treatment on the
breast and colon cancer cell lines comparison with  the single treatment.
The antioxidant nature of genistein has  confirmed by in-vitro antioxidant
studies which showed good results at different concentrarions and also the silibinin
has also shown good cytoprotective activity in-vitro in single and in combination
treatments.
The results of present investigation proved that the compounds Silibinin and
Genistein was found to be effective in inhibiting cancer growth by in-vitro screening
The present studies also suggest that the flavonoids are effective and alternative in
treatment of tumour and related disorders.
Further studies were essential to characterize and elucidate the detailed
mechanism of action of Silibinin and Genistein.
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